Filing Details

Accession Number:
0001209191-20-039080
Form Type:
4
Zero Holdings:
No
Publication Time:
2020-06-26 16:23:23
Reporting Period:
2020-06-24
Accepted Time:
2020-06-26 16:23:23
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1679082 Myovant Sciences Ltd. MYOV Pharmaceutical Preparations (2834) 000000000
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1714080 Camilo Juan Ferreira Arjona C/O Myovant Sciences Inc.
2000 Sierra Point Parkway, 9Th Floor
Brisbane CA 94005
Chief Medical Officer No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2020-06-24 10,946 $7.78 156,061 No 4 M Direct
Common Stock Acquisiton 2020-06-24 6,500 $7.78 162,561 No 4 M Direct
Common Stock Disposition 2020-06-24 17,446 $20.00 145,115 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (Right to Buy) Disposition 2020-06-24 10,946 $0.00 10,946 $7.78
Common Stock Stock Option (Right to Buy) Disposition 2020-06-24 6,500 $0.00 6,500 $7.78
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
245,000 2027-08-14 No 4 M Direct
80,550 2028-04-15 No 4 M Direct
Footnotes
  1. Shares sold pursuant to a 10b5-1 trading plan.
  2. 1/4 of the common shares underlying this option vested on August 15, 2018, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. Of the vested portion of this option, 130,000 shares cannot be exercised for 12 months commencing on August 26, 2019, subject to certain exceptions provided by the Reporting Person's applicable option agreement.
  3. 1/4 of the common shares underlying this option vested on April 16, 2019, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date. Of the vested portion of this option, 27,204 shares cannot be exercised for 12 months commencing on August 26, 2019, subject to certain exceptions provided by the Reporting Person's applicable option agreement.